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Background: This study examined the relationship of medication adherence to frequency of pulmonary exacerbation and rate of decline in FEV1%
predicted (FEV1).
Methods: 95 CF patients aged 6 years or older and prescribed a pulmonary medication, were enrolled in a longitudinal retrospective review of
medication adherence and health outcomes (the occurrence and frequency of intravenous (IV) antibiotic treatments and FEV1) over 12-months.
Pharmacy refill records were used to calculate a medication possession ratio (MPR).
Results: Composite MPR predicted the occurrence of at least one pulmonary exacerbation requiring a course of IV antibiotics (IRR=2.34,
p=0.05), but not the frequency of exacerbations, after controlling for gender, baseline FEV1, and regimen complexity. Composite MPR predicted
baseline FEV1 (estimate=29.81, p= .007), but not decline in FEV1.
Conclusions: These results demonstrate a significant relation between medication adherence and IV antibiotics in CF patients, highlighting the
importance of addressing adherence during clinic visits to improve health outcomes.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Adherence; Cystic fibrosis; Health outcomes; Treatment; Pulmonary exacerbation1. Introduction
Chronic use of inhaled and oral therapies is the cornerstone
of maintaining lung health for cystic fibrosis (CF) patients [1].
While medications used chronically by CF patients are effective
relative to placebo in the context of clinical trials, there are littleAbbreviations: BMI, body mass index; FEV1, forced expiratory volume in
the first second; HLM, hierarchical linear model; IRR, incidence rate ratio; IQR,
interquartile range; MPR, medication possession ratio; PFT, pulmonary function
test; SD, standard deviation.
☆ Funding sources: NHLBI Grants R01 HL087997 and K23 HL075344.
⁎ Corresponding author at: Johns Hopkins University, Division of Pulmonary
and Critical Care Medicine, 5501 Hopkins Bayview Circle, 4B.74, Baltimore,
MD 21224, USA.
E-mail addresses: meakin1@jhmi.edu (M.N. Eakin), abilder1@jhmi.edu
(A. Bilderback), mboyle@jhmi.edu (M.P. Boyle), pmogayze@jhmi.edu
(P.J. Mogayzel), kriekert@jhmi.edu (K.A. Riekert).
1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.03.005data about the relationship between level of adherence to a
regimen and health outcomes in a real-world setting. This
knowledge is critical because a substantial body of literature
demonstrates that adherence to medications is poor among
people with CF. Objective data, including pharmacy refill
history and electronic medication monitors, show that levels of
medication adherence range from 67% for oral antibiotics to
31–53% for inhaled antibiotics, 53–79% for mucolytic agents,
and 41–72% for hypertonic saline [2–7]. Adding to the
challenge of accurately assessing adherence is that people
with CF are prescribed treatment regimens of varying
complexity, suggesting a need for a simple measure of global
adherence to pulmonary medications for use in clinical care.
Adherence to medications has been shown to be related health
outcomes in other illness, such as asthma. Adherence is related to
greater asthma morbidity, including increased symptoms and
healthcare utilization [8] functional impairment [9] and mored by Elsevier B.V. All rights reserved.
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specifically examined the relationship between medication
adherence and health outcomes in CF. Two small studies
examined the relationship using archival records but neither
found a significant correlation. One study found that adults rated
as nonadherent with unnamed medications tended to be
hospitalized more often (p=.08) [11], while the other found a
trend between adherence to mucolytic agents and lung function
(p=.10) [12]. Thus a key research area is to determine whether
nonadherence is associated with health outcomes and, if so, what
level of adherence to which drug is necessary to confer benefit.
Therefore, the purpose of this study was to examine the
relationship of medication adherence to health outcomes,
specifically the frequency of intravenous (IV) antibiotics to
treat pulmonary exacerbations and change in FEV1% predicted
over a 12-month period. This study also examined the validity
of a composite adherence score that combined adherence data
into a single score for the four medications of interest. We
hypothesized that low medication adherence would be associ-
ated with more frequent courses of IV therapy and lower
baseline lung function. Furthermore, we hypothesized that
patients with the highest adherence would have sustained
improvement in lung function. Some of the results of these
studies have been reported previously as abstracts [13,14].
2. Methods
Patients 6 years or older with CF were eligible if they had
been seen at the clinic for at least 18 months, and were
prescribed at least one of the following for a minimum of
12 months: dornase alfa, inhaled tobramycin, azithromycin, or
hypertonic saline. These drugs were selected because of the
strong evidence of their efficacy in improving lung health [1].
Furthermore, these medications are often prescribed for chronic
use, with a regular regimen prescribed for each drug (i.e., not
used as needed). This protocol was approved by the Johns
Hopkins Medicine Institutional Review Board.
2.1. Procedures
This study was a longitudinal retrospective review of
medication adherence over the previous year and health outcomes
over 18 months. Participants provided the name and contact
information for all pharmacies they used to obtainCFmedications
during the previous 12 months. Each pharmacy was faxed an
introductory letter requesting refill records, along with a copy of
the patient's signed consent form. Pharmacies were pursued until
records were received or the corporate privacy office explicitly
refused to release the records. Pulmonary function test (PFT)
results and frequency of pulmonary exacerbationswere abstracted
from the Cystic Fibrosis Foundation Patient Registry [15]. A
pulmonary exacerbation was defined as the administration of
intravenous antibiotics at home or in the hospital retrospectively
in the past 12 months. Treatment decisions for IV antibiotics were
made by a clinic physician based on symptoms, physical exam
findings, and objective measures (decrease in lung function, chest
x-ray changes and/or recent weight loss) consistent with the mostfrequently used definition of pulmonary exacerbations in clinical
trials [16]. The use of IV antibiotics was selected to define an
exacerbation in the study as it has been shown to be predictive of
mortality [17] and has been used in several recently published
outcome studies [18,19]. Thus, while it is not an ideal measure, it
is commonly used and predictive of poor outcomes. Baseline
FEV1% predicted was determined by selecting the highest FEV1
in the 6 months prior to the study period examined.
2.2. Measures
Patient pharmacy refill records were used to calculate a
medication possession ratio (MPR), defined as the sum of all days
of medication supply received, divided by the number of days the
medicationwas prescribed for chronic use during the study period
[20]. The number of days in the hospital was removed from the
denominator to account for days participants did not use their
home supply of medications. MPRs were calculated for each of
the targeted medications individually, with values truncated to
100%. The MPRs of each medication were averaged across all
medications to obtain the Composite MPR. If an individual was
prescribed only one drug, then the Composite MPR would be
equal to his or her MPR for that individual drug. The MPR
calculations were adjusted for medication cycled every-other
month (e.g., inhaled tobramycin), such that a 28 or 30 day supply
but was recorded as a 60 day supply.
The primary outcome variable was the number of courses of
IV antibiotics to treat a pulmonary exacerbation in the
12 months prior to the consent date, as this period was
concurrent with the pharmacy records used to calculate MPR.
Lung function, as measured by FEV1% predicted [21], was a
secondary outcome. Pulmonary function tests (PFTs) conducted
14 days before and after a course of IV antibiotics were
removed from these models.
Previous research has identified a number of factors related
to pulmonary exacerbations and lung function, which were
controlled for in the examination of the relation between
medication adherence and health outcomes. Potential covariates
included were gender, age, median household income by zip
code, nutritional status (measured by body mass index or BMI
for adult patients or BMI for age for pediatric patients [22] using
CDC growth charts), baseline lung function, and a positive
culture for pseudomonas aeruginosa in the concurrent
12 months. Regimen complexity (the sum of chronic pulmonary
medications on a scale of 0–4) was included as another
approximation of disease severity.
2.3. Statistical analyses
Given the high number of potential covariates and small
sample size, we examined the bivariate relation between each
predictor and the two outcomes. Only covariates that signifi-
cantly predicted each outcome variable (lung function and
pulmonary exacerbation) were included in a final multivariate
model. Because of the high proportion of participants having no
exacerbations, zero-inflated Poisson regression models were
conducted to predict the occurrence and frequency of
Table 1
Baseline characteristics (N=95).
Age in years, Mean (SD) 20.9±11.9
7–18 years old 47(49.7%)
18+ years old 48(50.3%)
Gender, n(%) Male 46(48.9%)
Ethnicity, n(%) Caucasian 88(93.7%)
Median household income by zip code, Mean (SD) $59,351±$21,682
Homozygous ΔF508 47 (50.5%)
Pancreatic insufficient 89(93.6%)
CF-related diabetes 7(7.4%)
Baseline FEV1% predicted, Mean (SD) 80.1±24.8
BMI, Mean (SD) 20.3±3.6
Pseudomonas Aeruginosa positive
culture in concurrent 12-months
32 (33.7%)
Pulmonary exacerbations in concurrent 12-months n(%)
0 57 (60%)
1–2 22(23.2%)
3 + 16(16.8%)
Prescribed drugs in regimen n (%)
Pulmozyme 90 (95%)
Azithromycin 76 (80%)
Inhaled Tobramycin 65 (68%)
Hypertonic Saline 25 (26%)
Regimen complexity (n of drugs)
1 drug 13(14%)
2 drugs 22 (23%)
3 drugs 41(43%)
4 drugs 19 (20%)
Fig. 1. Medication Possession Ratio (MPR) boxplot by drug.
Fig. 2. Composite MPR by age groups.
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Composite MPR. We used a random effects model with
restricted maximum likelihood to predict both the intercept
(baseline FEV1% predicted) and slope (change in FEV1%
predicted) over 12 months. This model is suitable for
longitudinal data analyses because it produces serial correla-
tions among measurements performed on several occasions.
Analysis and data management were performed using SAS v
9.2 (SAS Institute, Cary, NC). Follow-up analyses were
completed with each individual drug MPR as the predictor to
examine the relation between adherence to individual drugs and
health outcomes.
3. Results
3.1. Participants
A total of 107 people with CF consented to join the study.
We received complete refill records for 101 (94%) participants
and six participants did not have baseline lung function results
because they had no clinic visits during the 6-month baseline
period, resulting in a final sample of 95 participants (Table 1).
Those excluded from the analyses did not differ from those
included on baseline demographics.
3.2. Prescribed regimen and overall adherence
Almost all participants were prescribed dornase alfa (95%);
80% were prescribed azithromycin, 68% inhaled tobramycin,
and 26% hypertonic saline. The most common regimen wasazithromycin, dornase alfa, and inhaled tobramycin (37%). The
median MPR for each medication ranged from 49% (Inter-
quartile Range (IQR)=0%–85%) for hypertonic saline to 76%
(IQR=49%–90%) for azithromycin (Fig. 1).
There were no statistically significant differences in MPRs
among the different medications. The median Composite MPR
was 63% (IQR=39%–80%; Range 0%–100%). The MPR for
each individual drug was significantly correlated with the
Composite MPR, ranging from Spearman's rho= .52 for
hypertonic saline to Spearman's rho= .80 for dornase alfa (all
p valuesb .01). However, the Composite MPR was not
correlated with regimen complexity (number of medications
prescribed; Spearman's rho=−0.07, p= .53). There were no
statistically significant age differences in medication adherence
(pb0.14 see Fig. 2).
3.3. Association between adherence and health outcomes
3.3.1. Pulmonary exacerbations
During the 12-month observation period, 40% of the
participants (n=38) had at least one course of IV antibiotics
to treat a pulmonary exacerbation (Table 1). Bivariate analyses
indicated that gender, regimen complexity, baseline FEV1%
predicted, and Composite MPR were the only variables that
Table 2
Zero-Inflated Poisson regression predicting pulmonary exacerbations over 12-
months (N=95).
IRR* Standard error P value
Dichotomous outcome (occurrence)
Female gender 1.30 0.621 0.04
Baseline FEV1% predicted 0.03 0.01 0.07
Regimen complexity −0.51 0.35 0.15
Composite MPR 2.34 1.18 0.05
Continuous outcome (frequency)
Female gender 1.75 0.42 0.02
Baseline FEV1% predicted 0.98 0.04 b0.001
Regimen complexity 1.13 0.15 0.33
Composite MPR 1.23 0.49 0.59
*IRR=incidence rate ratio.
Table 3
Mixed effect modeling estimates of FEV1% predicted over 12-months (N=95).
Variable Estimate Standard error P value
BMI −1.93 0.62 0.003
Regimen complexity −9.19 2.34 0.002
Linear slope of FEV1% 0.97 0.34 0.005
Quadratic slope of FEV1% −0.08 0.02 0.001
Composite MPR 29.81 8.48 0.007
Slope of FEV1%∗Composite MPR 0.26 0.37 0.49
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antibiotics and were included in the final model. Table 2
presents the results of the zero-inflated Poisson regression,
which had a good fit to the distribution of pulmonary
exacerbations (Vuong test z=2.97, p=0.002). Female gender
and lower Composite MPR significantly predicted having one
or more courses of IV antibiotics to treat a pulmonary
exacerbation during the year (Fig. 3). In contrast, lower baseline
FEV1% predicted and female gender were the only variables
associated with the frequency of exacerbations. When analyses
with the MPR of each individual drug were repeated, a trend
was evident for an association between lower azithromycin
MPR and having a pulmonary exacerbation (IRR=2.23,
p=0.07). No other individual drug MPR was associated with
the occurrence or frequency of a pulmonary exacerbation.
3.3.2. Lung function
Because of our inclusion criteria, all participants had to have
at least 2 clinic visits in the 18 months observation period. The
number of PFT's per participant during the observation period
ranged from 3 to 15, after removing PFTs during courses of IV
antibiotics. Bivariate analyses indicated that regimen complex-Fig. 3. Pulmonary Exacerbations by Composite MPR (Probability of number of
pulmonary exacerbations by Composite MPR while controlling for gender,
regimen complexity and baseline lung function).ity, BMI, and Composite MPR were the only variables that
significantly predicted lung function and were included in the
model. Slope of FEV1 was modeled with a linear, as well as a
quadratic, function. A comparison of the model fit statistics
demonstrated that the model without the quadratic term for time
had an AIC index=5069.2 and the model with the quadratic
term had an AIC index=5046.6, indicating a better model fit
with the quadratic term. Furthermore, the difference in chi-
square model fit statistic was 10.41, Pb0.01, indicating a better
model fit with the quadratic term. The Composite MPR was a
significant predictor of the fixed effect of the intercept (i.e.,
baseline FEV1% predicted) and accounted for an additional
11% of the variance in the intercept (Table 3). However, the
Composite MPR was not a significant predictor of change in
slope (estimate=0.26, p=0.49) and did not account for any
additional variance in the slope of FEV1% predicted. We
categorized adherence into three groups – MPR=80–100%,
MPR=50–80%, and MPRb50% – to request least squared
means at quarter 1 and quarter 4. Fig. 4 shows that participants
who had a Composite MPR of ≥80% had a mean FEV1%
predicted that increased 0.53%. In contrast, those with a
Composite MPR of 50–80% and b50% experienced a decline
of 2.22% and 0.39% in their lung function, respectively;
however, the group differences in slope are not statistically
significant. These models were repeated using MPR for each
individual drug; the dornase alfa MPR (estimate=28.11,Fig. 4. Lung function over time by adherence category after controlling for
regimen complexity and BMI.
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p=0.03) were the only drugs that predicted baseline FEV1,
respectively, accounting for an additional 9% and 7% of the
variance in the intercept. No individual drug MPR predicted
change in FEV1% predicted slope.
4. Discussion
In this retrospective longitudinal study, we examined the
relation between medication adherence and health outcomes for
people with CF. Consistent with other studies using objective
measures, participants on average demonstrated poor adherence
to all pulmonary medications, with high variability across
participants, regardless of the medication or delivery method.
This is the first study to demonstrate an association between
medication adherence and the occurrence of a course of IV
antibiotics to treat pulmonary exacerbations. Medication
adherence was also associated with baseline FEV1 predicted
although it did not predict change in lung function over 12-
months. The lack of findings on the rate of decline in lung
function is not surprising since the most commonly used
therapist have not been shown to reduce the rate of FEV1 but
rather to maintain lung function compared to placebo [23,24].
Furthermore, the use of FEV1 decline as an endpoint is difficult
due to the individual variability in FEV1, which would require
long study durations and large sample sizes [23]. While not
statistically significant, it is interesting that lung function was
maintained in those patients with adherence N80%, while those
with b80% adherence experienced a loss in lung function. This
observation merits further study.
Adherence to one medication was highly correlated with
adherence to the other medications, and all of the medications
evaluated in this study have been shown individually to
improve CF outcomes in randomized trials. Unfortunately, no
comparative effectiveness trials have been conducted to
demonstrate whether one medication is more effective than
another, or if there is a cumulative or synergistic effect of using
multiple medications. When there is no clear primary outcome,
a composite variable can address the issue of multiplicity
without having to adjust for type 1 error [25]. Therefore, a
composite adherence score, rather than evaluation by a single
drug, may best reflect the cumulative impact of the drug
regimen on the participant's health. Indeed, we found that the
Composite MPR was as good or better a predictor of requiring
at least one course of IV antibiotics and lung function than any
individual drug MPR. We did, however, identify the following
differences among individual drugs: dornase alfa and inhaled
tobramycin adherence were positively associated with higher
baseline FEV1% predicted, and there was a trend for an
association of azithromycin nonadherence with having a
pulmonary exacerbation. These findings are similar to other
studies that have demonstrated that dornase alfa and inhaled
tobramimycin sustain improvement in FEV1 compared to
placebo [26–29]. However, results are mixed regarding the
efficacy of these medications on pulmonary exacerbations, with
some studies reporting a statistically significant association
[16,26,29], and other studies reporting no association [27,30].Previous studies have demonstrated that azithromycin is
associated with fewer pulmonary exacerbations regardless of
improvement in FEV1, similar to our findings [1,31,32]. It
should be noted that the absence of correlation between health
outcomes and MPRs for each individual drug may be due to
small sample size and thus a lack of power to detect differences;
this warrants further evaluation before drawing a conclusion
about the relative value of adhering to each medication.
These results suggest that medication adherence is an
important prognostic indicator for the likelihood of having a
pulmonary exacerbation. This highlights the need for physi-
cians to incorporate assessment of medication adherence to
more accurately predict the likelihood of a pulmonary
exacerbation and promote more aggressive intervention, in
addition to routinely monitoring current lung function and
pulmonary symptoms. Physicians have long been encouraged
to assess adherence to medications during each clinic visit;
however, most rely on clinical judgment or patient self-report
to rate a patient's level of medication adherence. Both methods
of adherence assessment regardless of treatment team role
(e.g., physician, nurse or respiratory therapist) have been
shown to be inaccurate for identifying patients who are
nonadherent [33–36]. This study relied on prescription refills
as objective data from which to calculate adherence. As the use
of e-prescribing and electronic medical records increases,
refill-derived adherence scores could be calculated automat-
ically and inserted into the patient record offering a cost-
effective strategy for obtaining this clinically useful informa-
tion. Beyond assessing adherence, counseling nonadherent
patients is frequently cited as a major source of frustration for
healthcare providers [37]. One potential strategy for improving
medication adherence is to discuss with patients the associa-
tion between medication adherence and health outcomes and
tailor this message to the patient's current level of adherence.
Qualitative interviews with adult CF patients indicate that
patients are more likely to take a medication if they know it is
working for them or others [38]. According to social learning
theory, provision of health feedback using clinical outcome
data increases patients' outcome expectations for the targeted
health behavior, which may lead to an increased likelihood that
they will change [39]. Furthermore, interventions such as
problem-solving may be helpful for CF care teams to use with
their patients to identify and collaborate on potential solutions
for barriers to medication adherence [40].
Individuals with CF already experience significant treatment
burden due to the length of time required to complete their
treatments. A greater understanding of the dose–response
relationship for each drug will provide valuable information to
clinical care teams about expected response to treatment, the
decision to initiate new medications, and the need for
supportive counseling about the level of adherence required
for the patient to see treatment benefit. Therefore, it is important
for clinical outcomes research to begin including objectively
measured adherence as a covariate when evaluating the efficacy
of new and existing medications over time to better understand
how the benefits (and risks) of a medication are influenced by
treatment adherence.
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retrospective review of the association between medication
adherence and health outcomes over a one-year period, thus
limiting our ability to see longitudinal change in health
outcomes. Pharmacy refill records provide overall estimates
of the maximum possible adherence, but they do not confirm
ingestion or appropriate patterns of use and cannot account for
stockpiling medicine [41]. In CF it is not possible to obtain a
measure of actual medication usage because electronic
monitoring devices are not available for most nebulizers.
However, as noted above, refill data are a cost-effective strategy
for obtaining objective data and are more accurate than self-
report [42]. There are many predictors of CF outcomes that were
not included in this analysis. Because of our sample size, we
limited our predictor variables to include only variables
associated with the health outcomes at the bivariate level.
Some previously identified associations, such as median
household income by zip code [43], were not found in our
study. However, these variables may not have been sensitive for
use in a single site study where most participants come from a
homogeneous geographic area. We did not include oral
antibiotics in our definition of a pulmonary exacerbation
because often we could not discern the reasons for prescribing
(e.g., exacerbation versus sinus infection); this may have
resulted in underestimating the frequency of mild exacerba-
tions. Finally, physician perceptions of patient adherence may
affect their decision to treat with IV antibiotics. Because 1)
physicians did not have access to the pharmacy records, and 2)
studies have shown physicians are inaccurate in identifying
nonadherence [33,35,36], we do not feel that this explains the
association between adherence and exacerbations. Given the
above caveats, and the short duration of follow-up, it is
remarkable that we found a relationship between nonadherence
and the occurrence of pulmonary exacerbations. These results
highlight the need for future research with larger sample sizes
from a diverse population of individuals with CF and for a
longer period of time to determine if the association between
medication adherence and health outcomes persists after
controlling for other predictors, and to tease out the relationship
between illness severity, regimen complexity, and adherence.
The results from this study demonstrate for the first time that
poor CF medication adherence is a significant predictor of
having a pulmonary exacerbation during a concurrent 12-month
period and baseline lung function. This result highlights the
importance of both medication adherence in the treatment of CF
and of physicians assessing adherence during clinic visits to
promote appropriate interventions to improve adherence and
subsequent health outcomes.
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